Ocrelizumab proves superior to first-line therapies in early RRMS, promoting better outcomes.
Long-term data spanning a decade validate Ocrelizumab’s sustained efficacy and safety across MS stages, enhancing patient management.
At the 2024 American Academy of Neurology conference, significant findings were presented regarding Ocrelizumab's efficacy and safety in multiple sclerosis (MS) treatment. These included insights from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort, demonstrating low disease activity over four years of Ocrelizumab therapy in treatment-naive patients with high-activity, early-stage relapsing-remitting MS. ...
